Chad Lomas, MD
Allergy & Immunology · Centennial, CONPI 1265771026
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.9% of the total across 254 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 27 manufacturers reported payments, led by AstraZeneca at 24.5% of the total. 2025 is the largest year on record at $2,621, more than ten times the $22 reported in 2020.
Across 254 payments — averaging $24.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Sanofi$812
- GSK$643
- Pfizer$405
- Takeda Pharmaceuticals U.S.A., Inc.$347
- Pharming Healthcare, Inc.$264
- plus $2K from 21 others
What the payments were for
- Consulting fees$421%
- Food & beverage$5,94597%
- Education$1492%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 42 | $1,504 |
| Sanofi | 50 | $812 |
| GSK | 33 | $643 |
| Pfizer | 25 | $405 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $347 |
| Pharming Healthcare, Inc. | 6 | $264 |
| Biocryst US Sales Co., LLC | 8 | $244 |
| Novartis | 12 | $244 |
| Genentech USA, Inc. | 11 | $218 |
| Regeneron Healthcare Solutions, Inc. | 8 | $191 |
| Grifols USA, LLC | 8 | $153 |
| Sanofi-aventis U.S. LLC | 2 | $149 |
| AbbVie | 6 | $148 |
| Alk-abello, Inc | 2 | $119 |
| CSL Behring | 4 | $112 |
| ARS Pharmaceuticals Operations, Inc. | 4 | $101 |
| Amgen | 3 | $84 |
| Kaleo, Inc. | 3 | $77 |
| Organon | 4 | $45 |
| ADMA Biomanufacturing LLC | 2 | $42 |
| Optinose US, Inc. | 2 | $41 |
| Blueprint Medicines Corporation | 1 | $40 |
| Teva Pharmaceuticals USA, Inc. | 2 | $40 |
| Boehringer Ingelheim | 2 | $37 |
| Galderma Laboratories, L.p. | 2 | $30 |
| Lilly USA, LLC | 1 | $24 |
| Arcutis Biotherapeutics, Inc. | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,137 in reported general payments places this provider in the 65th percentile of 89 allergy & immunology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 42 | $177,038 |
| Dupixent SyringeDupilumab | 25 | $132,806 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 70 | $52,045 |
| Breo ElliptaFluticasone/Vilanterol | 66 | $40,479 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 38 | $33,455 |
| Advair HfaFluticasone Propion/Salmeterol | 42 | $27,410 |
| DuleraMometasone/Formoterol | 36 | $17,878 |
| SymbicortBudesonide/Formoterol Fumarate | 58 | $15,834 |
| Arnuity ElliptaFluticasone Furoate | 25 | $10,964 |
| Spiriva HandihalerTiotropium Bromide | 13 | $7,871 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 49 | $6,921 |
| Epinephrine | 23 | $5,736 |
| Qvar RedihalerBeclomethasone Dipropionate | 12 | $4,946 |
| Ipratropium Bromide | 107 | $3,454 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 100 | $2,774 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $643 | $103,488161 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,504 | $49,28996 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $40 | $4,94612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 89 allergy & immunology providers in Colorado.
Other allergy & immunology in Centennial
- Edan SaridCentennial$60K
- Rohit KatialDenver$758K
- Nicole BarberisLakewood$351K
- Christopher WebberColorado Springs$350K
- Jeffrey RumbyrtLakewood$348K
- Eric CaplanColorado Springs$290K
- Eileen WangDenver$274K
- Donald LeungDenver$208K
- Robert NathanColorado Springs$130K
- Katherine McCormackLouisville$90K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.